Myriad Genetics (MYGN) grants 173196 RSUs, withholds 14683 shares for tax

Rhea-AI Filing Summary

MYRIAD GENETICS INC Chief People Officer Shereen Solaiman received a large equity award and had shares withheld for taxes. On March 12, 2026, she was granted 173196 time-based restricted stock units under the 2017 equity incentive plan, vesting in three equal annual installments starting on the first anniversary of the grant.

On March 13 and 14, 2026, the company withheld 8899 and 5784 shares of common stock, respectively, to cover tax obligations tied to vesting of previously granted restricted stock units, based on a share price of $4.6600. After these tax-withholding dispositions, she directly holds 267801 shares of common stock.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Solaiman Shereen

Role Chief People Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	5,784	$4.66	$27K
Tax Withholding	Common Stock	8,899	$4.66	$41K
Grant/Award	Common Stock	173,196	$0.00	--

Holdings After Transaction: Common Stock — 267,801 shares (Direct)

Footnotes (1)

1. Consists of time-based restricted stock units granted pursuant to the Issuer's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 13, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Solaiman Shereen

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UT 84116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		A		173,196(1)	A	$0	282,484	D
Common Stock	03/13/2026		F		8,899(2)	D	$4.66	273,585	D
Common Stock	03/14/2026		F		5,784(2)	D	$4.66	267,801	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of time-based restricted stock units granted pursuant to the Issuer's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date.

2. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 13, 2026.

Remarks:

	By: Justin Hunter For: Shereen Solaiman	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did MYRIAD GENETICS (MYGN) report for Shereen Solaiman?

MYRIAD GENETICS reported a grant of 173196 restricted stock units to Chief People Officer Shereen Solaiman, plus two tax-withholding dispositions totaling 14683 shares tied to vesting of earlier awards. These were compensation-related, not open-market trades.

How many restricted stock units did MYGN grant to its Chief People Officer?

MYRIAD GENETICS granted 173196 time-based restricted stock units to its Chief People Officer. Each unit represents one share of common stock and vests in three equal annual installments beginning on the first anniversary of the March 12, 2026 grant date.

How do the MYGN restricted stock units granted to Shereen Solaiman vest?

The MYRIAD GENETICS restricted stock units vest in three equal annual installments. Vesting starts on the first anniversary of the March 12, 2026 grant date, with each installment converting into common shares if the vesting conditions are satisfied.

Why did MYRIAD GENETICS withhold MYGN shares from Shereen Solaiman?

MYRIAD GENETICS withheld 8899 and 5784 shares of common stock to satisfy tax withholding obligations when previously granted restricted stock units vested. The number of shares withheld was based on the closing price of $4.6600 on March 13, 2026.

How many MYGN shares does Shereen Solaiman own after these transactions?

After the reported transactions, Chief People Officer Shereen Solaiman directly holds 267801 shares of MYRIAD GENETICS common stock. This figure reflects the grant and subsequent tax-withholding dispositions reported in the March 2026 Form 4 filing.

Were the MYGN insider transactions open-market purchases or sales?

The Form 4 shows no open-market purchases or sales. It reports one grant of restricted stock units and two F-code tax-withholding dispositions, where shares were withheld by MYRIAD GENETICS to pay taxes related to vesting of existing equity awards.